Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Pfizer Inc.'s (NYSE:PFE) lung cancer drug Xalkori was tentatively rejected by an advisory board on Friday for use in the U.K.'s National Health Service. Claiming the drug, also called crizotinib, was too expensive, the National Institute for Health and Care Excellence (NICE) recommended against approving the drug for use in the cash-strapped universal healthcare system, despite Pfizer’s offer of a discount. Pfizer previously said it would cover part of the £51,179 ($80,000) cost of treatment with Xalkori.
Help employers find you! Check out all the jobs and post your resume.
